Bronchiectasis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Bronchiectasis Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Bronchiectasis Pipeline Outlook
Key Takeaways from Bronchiectasis Pipeline Report
In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis.
In May 2025, Genentech Inc. announced a phase I study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease.
In May 2025, Mannkind Corporation conducted a phase 3 study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection.
DelveInsight's Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
Stay ahead with the most recent pipeline outlook for Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs
Bronchiectasis Emerging Drugs Profile
Benralizumab: AstraZeneca
Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.
S1226: SolAeroMed
S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the ß-adrenergic agonists and thus complements, rather than replaces, existing treatments.
Brensocatib: Insmed
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.
The Bronchiectasis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market
Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Bronchiectasis Drugs
Pulmonary Fibrosis Companies
AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Bronchiectasis Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Unveil the future of Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers
Scope of the Bronchiectasis Pipeline Report
Coverage- Global
Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Bronchiectasis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Bronchiectasis – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Benralizumab: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
S1226: SolAeroMed
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CSL787: CSL Behring
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
AP-PA02: Armata Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Bronchiectasis Key Companies
Bronchiectasis Key Products
Bronchiectasis- Unmet Needs
Bronchiectasis- Market Drivers and Barriers
Bronchiectasis- Future Perspectives and Conclusion
Bronchiectasis Analyst Views
Bronchiectasis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. UnitedHealth Group Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. 2. Merck Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CTV News
18 hours ago
- CTV News
Breakthrough revelead in sickle cell treatment options
Sickle cell disease is a genetic condition that affects hundreds of thousands of people round the world. Health reporter Pauline Chan details the latest development in treatment options.
National Post
21 hours ago
- National Post
Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records
Article content NEW YORK — Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real historical medical charts. Built on the same HIPAA-compliant platform that powers live summarization of electronic health records (EHRs) in hospital settings, the simulation lets clinicians explore rare, complex cases from hundreds of years ago without patient risk. Article content CEO Vince Hartman calls it 'a Microsoft Flight Simulator for medicine,' enabling diagnostic training on authentic data with no need for EHR integration. 'Three years after ChatGPT, fewer than 1% of physicians have ever seen an AI full medical record summary,' he says. 'We're changing that.' Article content Each case begins with an AI-generated summary distilled from original, centuries-old handwritten documents. Clinicians explore the structured chart, from history of present illness to labs and vitals, and receive simulated updates based on actual clinical observations. 'It's not a quiz. It's about engaging clinical reasoning in a sandbox where doctors can make decisions and learn from them,' Hartman explains. Article content The simulation is built on Abstractive Health's existing summarization and retrieval-augmented generation (RAG) and agentic AI platform. Leveraging advanced OCR and a robust AI summarization pipeline, it can also process handwritten records and turn scribbled notes into readable clinical narratives. The summarization technology is currently being piloted at Weill Cornell Medicine in a research collaboration to assist with writing Emergency Medicine handoff notes. Abstractive Health is also preparing to roll out the experience to Canadian outpatient clinics through a partnership with Canada's WELL Health Technologies that followed an investment and distribution deal inked last year. Article content Abstractive Health's broader goal is to bring clinicians into meaningful, hands-on engagement with AI. 'We're not just saving time – we're helping doctors think better,' Hartman says. 'This is about curiosity, growth, and elevating clinical skill.' Article content Clinical Time Machine is available now through Abstractive's platform for free. Article content Abstractive Health retrieves medical records, generates trusted AI summaries, and answers complex clinical questions. Its platform is used by clinicians nationwide and is currently in pilots with Well Health and Weill Cornell Medicine. A top 3 company in the 2024 VA AI Tech Sprint, Abstractive is backed by the NSF and has been featured by Forbes 30 Under 30. Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content
